Cytokines as potential biomarkers of liver toxicity induced by Dioscorea bulbifera L.

BioScience Trends

Volumn 8, Issue 1, 2014, Pages 32-37

  Sheng, Yuchen ^a   Ma, Yibo ^a   Deng, Zhongping ^a   Wang, Zhengtao ^a   Ji, Lili ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

CD30L; Cytokines; Dioscorea bulbifera L.; Hepatotoxicity; IL 3

Indexed keywords

ACETIC ACID DERIVATIVE; ACETIC ACID ETHYL ESTER; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CD30 LIGAND; CYTOKINE; HERBACEOUS AGENT; INTERLEUKIN 3 RECEPTOR; PLANT EXTRACT; TNFSF8 PROTEIN, MOUSE;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; TOXIC HEPATITIS; YAM;

ACETATES; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CD30 LIGAND; CYTOKINES; DIOSCOREA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICE; PLANT EXTRACTS; RECEPTORS, INTERLEUKIN-3;

EID: 84896889977     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.8.32     Document Type: Article

References (36)

1. Jiangsu New Medical College. Chinese Dictionary (Second Volume). Shanghai Science and Technology Press, Shanghai, China, 1977; pp. 2059-2061.
2. Liu JR. Two cases of toxic hepatitis caused by Dioscorea bulbifera L. Adverse Drug Reactions J. 2002; 2:129-130.
3. Wang JM, Liang QN, Ji LL, Liu H, Wang CH, Wang ZT. Gender-related difference in liver injury induced by Dioscorea bulbifera L. rhizome in mice. Hum Exp Toxicol. 2011; 30:1333-1341.
4. Wang JM, Liu H, Ji LL, Wang ZT. Study of the hepatotoxicity induced by Dioscorea bulbifera L. rhizome in mice. BioSci Trends. 2010; 4:79-85.
5. Ma M, Jiang Z, Ruan J, Tan X, Liu J, Wang C, Zha XM, Zhang L. The furano norclerodane diterpenoid disobulbin-D induces apoptosis in normal human liver L-02 cells. Exp Toxicol Pathol. 2012; 64:611-618.
6. Su D, Li L. Trends in the use of complementary and alternative medicine in the United States: 2002-2007. J Health Care Poor Underserved. 2011; 22:296-310.
7. Nin Chau T, Cheung WI, Ngan T, Lin J, Lee KW, Tat Poon W, Leung VK, Mak T, Tse ML. Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method (RUCAM). Clin Toxicol (Phila). 2011; 49:34-39.
8. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135:1924-1934.
9. Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM, Khor C, Lim SG. Drug-induced liver injury at an Asian center: A prospective study. Liver Int. 2007; 27:465-474.
10. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008; 47:1363-1370.
11. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. Biomarker method validation in anticancer drug development. Br J Pharmacol. 2008; 153:646-656.
12. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008; 245:194-205.
13. Ruhl CE, Everhart JE. Diurnal variation in serum alanine aminotransferase activity in the US population. J Clin Gastroenterol. 2013; 47:165-173.
14. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010; 138:2246-2259.
15. Laverty HG, Antoine DJ, Benson C. The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol. 2010; 66:961-976.
16. Wang JM, Ji LL, Branford-White C, Wang ZY, Shen KK, Liu H, Wang ZT. Antitumor activity of Dioscorea bulbifera L. rhizome in vivo. Fitoterapia. 2012; 83:388-394.
17. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis. 2007; 27:339-350.
18. Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: Depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to pathology. Am J Ther. 2005; 12:254-261.
19. Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hepatotoxicity and repair: The role of sterile inflammation and innate immunity. Liver Int. 2012; 32:8-20.
20. Kumagai K, Kiyosawa, N, Ito K, Yamoto T, Teranishi M, Nakayama H, Manabe S. Influence of kupffer cell inactivation on cycloheximide-induced hepatic injury. Toxicology. 2007; 241:106-118.
21. Holt MP, Ju C. Mecahnsims of drug-induced liver injury. AAPS J. 2006; 8:E48-54.
22. Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev. 2012; 44:107-115.
23. Budowle B, Hudlow WR, Lee SB, Klevan L. Using a CCD camera imaging system as a recording device to quantify human DNA by slot hybridization. Biotechniques. 2001; 30:680-685.
24. Horie R, Watanabe T. CD30: Expression and function in health and disease. Semin Immunol. 1998; 10:457-470.
25. Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and infammatory diseases. Adv Exp Med Biol. 2009; 647:174-185.
26. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology. 2006; 118:143-152.
27. Simhadri VL, Hansen HP, Simhadri VR, Reiners KS, Bessler M, Engert A, von Strandmann EP. A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells. Biol Chem. 2012; 393:101-106.
28. Fuchiwaki T, Sun X, Fujimura K, Yamada H, Shibata K, Muta H, Podack ER, Kawauchi H, Yoshikai Y. The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in mice. Eur J Immunol. 2011; 41:2947-2954.
29. Somada S, Muta H, Nakamura K, Sun X, Honda K, Ihara E, Akiho H, Takayanagi R, Yoshikai Y, Podack ER, Tani K. CD30 ligand/CD30 interaction is involved in pathogenesis of inflammtory bowel disease. Dig Dis Sci. 2012; 57:2031-2037.
30. Chakrabarty S, Nagata M, Yasuda H, Wen L, Nakayama M, Chowdhury SA, Yamada K, Jin Z, Kotani R, Moriyama H, Shimozato O, Yagita H, Yokono K. Critical roles of CD30/CD30L interactions in murine autoimmune diabetes. Clin Exp Immunol. 2003; 133:318-325.
31. Fischer M, Harvima IT, Carvalho RFS, Moller C, Naukkarinen A, Enblad G, Nilsson G. Mast cell CD30 ligand is upregualted in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest. 2006; 116:2748-2756.
32. Eder M, Geissler G, Ganser A. IL-3 in the clinic. Stem cells. 1997; 15:327-333.
33. Johnson DE. Regulation of survival pathways by IL-3 and induction of apoptosis following IL-3 withdrawal. Front Biosci. 1998; 3:d313-324.
34. Bessler H, Bergman M, Salman H. Interleukin-3 and stress. Biomed Pharmacother. 2000; 54:299-304.
35. Anaya-Prado R, Toledo-Pereyra LH, Guo RF, Reuben J, Ward PA, Walsh J. The attentuation of hemorrhage-induced liver injury by exogenous nitric oxide, L-arginine, and inhibition of inducible nitric oxide synthase. J Invest Surg. 2003; 16:247-261.
36. Zhang XG, Xu P, Liu Q, Yu CH, Zhang Y, Chen SH, Li YM. Effect of tea polyphenol on cytokine gene expression in rats with alcoholic liver disease. Hepatobiliary Pancreat Dis Int. 2006; 5:268-272.